Jeantet advises investment funds Orbimed and Jeito Capital in connection with a EUR 65 million financing of Corteria Pharmaceuticals
Paris, September 8, 2023 – Jeantet has advised investment funds OrbiMed and Jeito Capital in connection with the series A financing of French biopharmaceutical company Corteria Pharmceuticals.
Corteria Pharmaceuticals, a biopharmaceutical company specializing in the development of transformative therapies for heart failure subpopulations, announced on September 7, 2023 a EUR 65 million series A financing, co-led by investment firms OrbiMed and and Jeito Capital, with the participation of the company’s historical shareholders.
Corteria Pharmaceuticals, was founded in 2021 by Philip Janiak, former head of cardiovascular research at Sanofi, and Marie-Laure Ozoux, former cardiovascular project leader at Sanofi, around two cardiovascular programs in-licensed from Sanofi.
OrbiMed (www.orbimed.com) is a New York-based international investment firm specializing in the healthcare sector, with $17 billion in assets under management.
Jeito Capital (www.jeito.life) is a Paris-based international investment firm focused on the biopharma sector, financing growth and accelerating cutting-edge medical innovation.